MetaCap

Arvinas (ARVN) vs Evolus (EOLS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Evolus (EOLS) has outperformed Arvinas (ARVN) over the past year, losing 4.8% versus a loss of 43.9%. Over five years, EOLS leads with a +14.4% price change compared with -91.8% for ARVN. Evolus is the larger company by market cap ($431.5 million vs $423.0 million), about 1.0 times the size.

Evolus converts more of its revenue into profit, with a net margin of -17.4% versus -30.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARVN-43.92%EOLS-4.82%
+40%-4%-48%
Nov 21, 20251 yearNov 20, 2026
ARVN-92.22%EOLS+2.19%
+187%+41%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARVN versus EOLS key metrics
MetricARVNEOLS
Share price$6.46$6.52
Market cap$423.03M$431.55M
1-day change-4.15%-6.86%
YTD return-45.53%-1.95%
1-year return-43.92%-4.82%
5-year return-91.75%+14.39%
Forward P/E—22.68
EPS (TTM)$-0.08$-0.48
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$262.60M$297.18M
Revenue growth (YoY)-0.30%+11.61%
Net income (latest FY)$-80.80M$-51.64M
Gross margin—66.33%
Operating margin-45.13%-10.99%
Net margin-30.77%-17.38%
52-week high$14.51$9.31
52-week low$6.33$3.86
Distance from 52-week high-55.48%-29.97%
Analyst consensusbuystrong_buy
Avg. price target upside+116.72%+136.20%
Average volume848.52K925.77K
Shares outstanding65.49M66.19M
Employees246365
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • EOLS has outperformed ARVN by 39.1 percentage points over the past year.
  • Evolus is more profitable, keeping -17.4 cents of every revenue dollar as net income versus -30.8 cents for Arvinas.
  • Evolus grew revenue faster in its latest fiscal year (+11.61% vs -0.30%).

About Arvinas

ARVN stock →

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.

Health Care · Biotechnology: Pharmaceutical Preparations · 246 employees

About Evolus

EOLS stock →

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.

Health Care · Biotechnology: Pharmaceutical Preparations · 365 employees

ARVN vs EOLS FAQ

Which is bigger, Arvinas or Evolus?

Evolus (EOLS) is larger, with a market capitalization of $431.55M compared with $423.03M for Arvinas (ARVN).

Which stock has performed better over the past year, ARVN or EOLS?

EOLS returned -4.82% over the past 12 months, compared with -43.92% for ARVN (price return, excluding dividends). Past performance does not predict future results.

Are Arvinas and Evolus in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons